Our most powerful physician supervised weight loss program. Tirzepatide-first with semaglutide as a physician-directed alternative — the dual-action GLP-1 that clinical trials show produces the most significant results.
Your physician selects the right medication for your body, health history, and weight loss goals. Tirzepatide is our primary recommendation for maximum results.
Tirzepatide activates both the GLP-1 and GIP receptors simultaneously — a dual mechanism that produces superior appetite suppression and metabolic improvement compared to single-receptor GLP-1 medications.
Clinical trial data shows tirzepatide produces the highest average weight loss of any GLP-1 class medication studied to date. For patients seeking maximum results, it is our physician's first recommendation.
Semaglutide is the most studied GLP-1 medication available. It activates the GLP-1 receptor to reduce appetite and slow gastric emptying. An excellent option for patients new to GLP-1 therapy or those with specific clinical considerations.
Your physician may recommend semaglutide if you are new to GLP-1 therapy, have specific clinical factors, or prefer to start with a single-receptor medication before stepping up.
Every prescription in this program is approved by a licensed physician who reviews your complete health history, BMI, medications, and clinical goals. The medication selection is a medical decision — not a patient choice. Your physician selects the most appropriate and safe option for you specifically.
Tirzepatide-first, physician directed. From $249/month. No insurance required. No consultation fee.
Physician review required. Compounded medications are not FDA-approved. BMI eligibility applies. Individual results vary.
* Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. Wilding JPH et al. (2021). Semaglutide in Adults with Overweight or Obesity. NEJM.